{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:24Z","timestamp":1792788504418,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaci.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:56:19Z","timestamp":1771358179000},"page":"1087-1098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1\u2013mediated chronic inflammatory skin diseases"],"prefix":"10.1016","volume":"157","author":[{"given":"Manja","family":"Jargosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Wasserer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Eigemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Raunegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Ding-Pfennigdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten B.","family":"Schmidt-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Florian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Saas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-2836","authenticated-orcid":false,"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.02.006_bib1","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2026.02.006_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Clinical practice. Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/jdv.16464","article-title":"European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology","volume":"34","author":"Ioannides","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.02.006_bib4","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00403-008-0892-8","article-title":"Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus","volume":"301","author":"Wenzel","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2026.02.006_bib7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1365-2133.2008.08522.x","article-title":"Subcellular activation site of caspase-3 in apoptotic keratinocytes observed in lichenoid tissue reaction","volume":"158","author":"Yoneda","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jid.2018.02.034","article-title":"Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis","volume":"138","author":"Lauffer","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-020-15466-8","article-title":"Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation","volume":"11","author":"Laurien","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.02.006_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.006_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/128076","article-title":"Necroptotic cell death signaling and execution pathway: lessons from knockout mice","volume":"2015","author":"Belizario","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2026.02.006_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nri.2016.147","article-title":"Programmed cell death as a defence against infection","volume":"17","author":"Jorgensen","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2026.02.006_bib15","article-title":"Identifying hidden drivers of heterogeneous inflammatory diseases","author":"Garzorz-Stark","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jaci.2026.02.006_bib16","article-title":"Advances in RIPK1 kinase inhibitors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2026.02.006_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129970","article-title":"Harnessing dual-mode RIPK1 ligands for cross-species anti-necroptosis inhibitor compounds","volume":"113","author":"Levente Petro","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2026.02.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129643","article-title":"Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors","volume":"100","author":"Petro","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2026.02.006_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2017.07.045","article-title":"Toll-like receptor 7\/8 agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in human subjects","volume":"141","author":"Garzorz-Stark","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.006_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00403-004-0507-y","article-title":"A simple reconstructed human epidermis: preparation of the culture model and utilization in in vitro studies","volume":"296","author":"Poumay","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2026.02.006_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8819560","article-title":"Cutaneous coinfection of cytomegalovirus and Mycobacterium chelonae accelerated by immunosuppression","author":"Tsutsumi","year":"2021","journal-title":"Case Rep Pathol 2021"},{"key":"10.1016\/j.jaci.2026.02.006_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.immuni.2011.09.020","article-title":"RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome","volume":"35","author":"Duprez","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2026.02.006_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2015.9","article-title":"Characterization of GSK\u2032963: a structurally distinct, potent and selective inhibitor of RIP1 kinase","volume":"1","author":"Berger","year":"2015","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jaci.2026.02.006_bib24","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3585","article-title":"Tofacitinib in hypertrophic lichen planus","volume":"100","author":"Seiringer","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2026.02.006_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ajd.13811","article-title":"Effective treatment of oral lichen planus with the JAK inhibitor baricitinib","volume":"63","author":"Moussa","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib26","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.jaci.2020.01.031","article-title":"Treatment of severe lichen planus with the JAK inhibitor tofacitinib","volume":"145","author":"Damsky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.006_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.02.006_bib28","series-title":"Updates on OLUMIANT\u00ae (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis","year":"2022"},{"key":"10.1016\/j.jaci.2026.02.006_bib29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.006_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.02.006_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.02.006_bib33","series-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","year":"2021"},{"key":"10.1016\/j.jaci.2026.02.006_bib34","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1039\/C7CC00667E","article-title":"Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein","volume":"53","author":"Yan","year":"2017","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.jaci.2026.02.006_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.130","article-title":"A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis","volume":"6","author":"Fauster","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jaci.2026.02.006_bib36","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00018-016-2198-x","article-title":"Generation of small molecules to interfere with regulated necrosis","volume":"73","author":"Degterev","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jaci.2026.02.006_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114641","article-title":"Non-canonical autophosphorylation of RIPK1 drives timely pyroptosis to control Yersinia infection","volume":"43","author":"Jetton","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2026.02.006_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/bjd\/ljae179","article-title":"Gasdermin E-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation","volume":"191","author":"Li","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.immuni.2016.06.007","article-title":"RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4","volume":"45","author":"Najjar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2026.02.006_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20250279","article-title":"RIPK1 autophosphorylation at S161 mediates cell death and inflammation","volume":"222","author":"Koerner","year":"2025","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.02.006_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12931-024-02670-z","article-title":"Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study","volume":"25","author":"Clot","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2026.02.006_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2026.02.006_bib43","doi-asserted-by":"crossref","first-page":"27715","DOI":"10.18632\/oncotarget.16016","article-title":"RIP3 deficiency ameliorates inflammatory response in mice infected with influenza H7N9 virus infection","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2026.02.006_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156341","article-title":"Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney","volume":"7","author":"Dunlap","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2026.02.006_bib45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.imbio.2009.06.013","article-title":"Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage","volume":"214","author":"Vermi","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2026.02.006_bib46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2026.02.006_bib47","first-page":"5597","article-title":"Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy","volume":"28","author":"Apalla","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaci.2026.02.006_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don\u2019t","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:38:37Z","timestamp":1781685517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0091674926000874"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.006","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1\u2013mediated chronic inflammatory skin diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}